Neuronal firing is a fundamental element of cerebral function; and, voltage-gated potassium (K þ ) channels regulate that firing through the repolarization of action potentials. Kv3-type channels (Kv3.1-Kv3.4) represent a family of voltage-gated K þ channels that have fast-spiking properties. Kv3.1 channel subunits are predominantly localized to cortical parvalbumin (PV)-positive, inhibitory interneurons. The firing properties of these interneurons participate in establishing the normal gamma oscillations and synchrony of cortical neuronal populations, thought to be the signature of higher information processing in human brain. Schizophrenia (SZ) is associated with abnormalities in cortical gamma synchrony and in information processing, particularly with dysfunction in working memory and executive function. Here, we report the distribution of Kv3.1b and Kv3.2 protein in normal human brain, showing that Kv3.1b is limited to neocortical areas, whereas Kv3.2 is abundantly represented in neo-and subcortical regions. In SZ cases, levels of Kv3.1b protein are decreased in the neocortex, but only in cases without antipsychotic drug (APD) treatment; Kv3.1 levels are normal in antipsychotic-treated cases. Kv3.2 is not different in distribution or in level between normal and SZ cases, nor influenced by APD, in any region tested. The apparent increase in Kv3.1b protein levels by APDs in SZ neocortex was confirmed in laboratory rodents treated with chronic APDs. These findings show a decrease in Kv3.1b channel protein in SZ neocortex, a deficit that is restored by APDs. This alteration could be fundamentally involved in the cortical manifestations of SZ and in the therapeutic response to APDs.
INTRODUCTION
Neuronal oscillations in the high gamma frequency ranges of electroencephalography (30-100 Hz), when synchronized across neuronal populations, are associated with productive cognitive and behavioral responses; their dysfunction is thought to be relevant for cognitive disorders. These gamma oscillations reflect the synchronized firing of task-relevant neuronal populations and are generated by the fast rhythmic inhibition of gammaaminobutyric acid (GABA)-containing inhibitory interneurons onto cortical pyramidal neurons. [1] [2] [3] Specifically, the fast-spiking interneurons involved in generating gamma synchrony are those that express the calcium-binding protein, parvalbumin (PV). Considerable evidence indicates that these interneurongenerated, synchronized gamma oscillations are disturbed in schizophrenia (SZ), 4 with deficits described in steady-stateevoked potentials, 5, 6 evoked, 7,8 induced 9,10 and resting-state oscillations. 11, 12 Moreover, several laboratories studying SZ tissue report molecular alterations in the PV-containing, fast-spiking, GABA interneurons within the prefrontal cortex, [13] [14] [15] which could be associated with a change in the cell firing pattern of the neurons that support gamma oscillations. These molecular studies show that glutamic acid decarboxylase 67 expression is reduced in the axon terminals of the PV-containing interneurons in SZ prefrontal cortex 16 and that subunits of the GABA receptor are increased. 13 Alterations in the function of PV-containing GABA interneurons with their fast-spiking properties could account for changes in gamma band oscillations and power in SZ, changes that could at least partially underlie cognitive manifestations in SZ. 13 Kv3 channels are voltage-gated K þ channels involved in the rapid repolarization of the action potential in neurons and they have a key role in the fast-spiking neuronal phenotype. 17 Kv3 channels are among the most brain specific of all known K þ channels. 18 Kv3.1b, the dominant splice variant of Kv3.1, and Kv3.2, channels in rodent cortex, are expressed in PV-positive GABAergic interneurons where they are necessary for facilitating the fast-spiking phenotype in those cells. 17 Indeed, Kv3.1 and Kv3.2 knockout (KO) mice show slower rates of neuronal repolarization than wild type; they show impaired highfrequency firing 19, 20 and demonstrate dysregulated gamma oscillations. 21, 22 Furthermore, the Kv3.1 KO mouse is characterized by the behavioral phenotype of locomotor hyperactivity and reduced sleep behavior, 23 mimicking aspects of the behavioral presentation of SZ. Interestingly, the expression of the Kv3.1b and Kv3.2 proteins reach peak levels during adolescence, 24 and also the time during human development when gamma oscillations increase dramatically and when characteristically SZ has its onset.
On the basis of these observations, we considered a role for altered Kv3 channels in SZ, a change that could be associated with its impaired gamma oscillations. We hypothesized a decrease in the protein expression of the Kv3 channel subunits in the cortex. Thus, we examined the distribution and expression of Kv3.1b and Kv3.2 channel proteins in human post-mortem brain and contrasted the expression levels of these proteins between SZ and control tissue.
MATERIALS AND METHODS

Human brain tissue
Human post-mortem brain tissue was obtained from the Dallas Brain Collection (Dallas, TX, USA), and its use was approved by the UTSW Institutional Review Board. Tissue was collected after obtaining consent from the next of kin along with their permission to obtain medical records and to hold a direct informant telephone interview. Characteristically highquality tissue was obtained with post-mortem intervals of o24 h, RNA integrity numbers 46.9 and low Agonal Scale Scores. 25 Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis was based on all available history, including an interview with a family member, and assigned from a consensus of at least three experienced research clinicians for each case. Blood toxicology screens for drugs of abuse, alcohol and prescription drugs, including antipsychotic drugs, were conducted on each case. Cases were excluded with a history of neurological disorders or axis I psychiatric disorders other than SZ, including active drug abuse.
At the time of brain acquisition and dissection, tissue samples were taken from representative brain regions, including dorsolateral-prefrontal (DLPFC), anterior cingulate (ACC), orbitofrontal (OFC), parietal (PC) and occipital (OC) cortices, and cerebellum (Cere), caudate nucleus (CN), nucleus accumbens (NAc), thalamus (Thal) and hippocampus (Hipp). The samples were dissected from the fresh brain when whole, frozen immediately in a mixture of dry ice and isopentane and stored at À 80 1C until their use. Tissue pH was determined as described previously. 25 The SZ Screening Cohort cases included 12 pair of SZ (nine SZ on-antipsychotic drug (APD) and three SZ off-APD) and 12 normal cases, matched as closely as possible, for age, gender, race, RNA integrity numbers and post-mortem interval (Supplementary Table 1 ). The SZ Off-APD Cohort cases included eight off-drug SZ cases (including the three SZ off-APD cases from the SZ Screening Cohort) and eight new case-matched normal cases (Supplementary Table 2 ). All SZ off-APD had a history from their family informant of being without APD treatment for 42 months before death and had no measurable APD in the blood. There were no significant differences in either of these cohorts between critical demographic variables of the cohorts.
The description of chronic APD treatment of rat, western blotting methods and quantitative polymerase chain reaction can be found in Supplementary Methods.
Statistics
The 10 human brain regions analyzed for Kv3 channels were clustered into two broad groups: neocortical (DLPFC, OFC, ACC, PCand OC) and subcortical/other regions (Nac, CN, Hipp and Thal). The cerebellum was included as a putative control region. In the SZ Screening Cohort, we tested for group differences in Kv3.2 immunoreactivity by cerebral region across the two groups (SZ; control) using mixed-model analysis of variance (ANOVA), where diagnosis was the independent variable and the protein levels in brain regions were the dependent variables. For Kv3.1b, ANOVA was performed only for the neocortex cluster, including DLPFC, PC and OC, because of the limited distribution of Kv3.1b immunoreactivity to human neocortex. We also examined correlations between Kv3.1b and Kv3.2 levels with age, post-mortem interval, RNA integrity numbers and pH for significance, to indicate an association between a protein change and the tissue quality measure, using Pearson's product-moment correlations. When correlations were observed, the factor was incorporated into the analysis as a covariate. In the SZ Off-APD Cohort, protein differences in the DLPFC, PC and OC were examined with t-tests. In the tissue from chronically treated animals, the comparison (using t-tests or one-way ANOVA) of Kv3.1b protein concentrations between APD (haloperidol and risperidone)-and water-treated tissue was tested in PFC. When significance was found using ANOVA, post hoc t-tests were performed. All tests were two-tailed, with the level of significance set at Pp0.05.
RESULTS
Distribution of Kv3.1b and Kv3.2 protein in normal human brain
The expression levels for the Kv3-type fast-spiking K þ channels in human brain have not been previously examined in detail, despite their extensive study in animal brain. 17 Therefore, we describe regional distribution patterns of Kv3.1b and Kv3.2 channel subunits in normal human tissue ( Figure 1 ). The western blot molecular weight bands of both Kv3.1b and Kv3.2 subunits in human tissue matched those from mouse tissue in having the same molecular weights as reported for mouse (B90 kDa for Kv3.1b 26 and B105 kDa for Kv3.2 27 ); in particular, the faint Kv3.1b signal was verified by comparison with normal and Kv3.1 KO mouse tissue, establishing confidence in the analysis ( Figure 1 ). Significant, albeit low, levels of Kv3.1b immunoreactivity were detected in the human neocortex and cerebellum, specifically in DLPFC, PC and OC, but not in subcortical grey matter regions, that is, there were undetectable levels in CN, NAc, Thal and Hipp. These outcomes confirm a limited distribution of low levels of Kv3.1b protein in normal human neocortex. In contrast, high levels of Kv3.2 immunoreactivity were found broadly distributed through cortical and subcortical brain, including DLPFC, Hipp, CN, NAc and Thal ( Figure 1 ). We selected regions with at least two times the intensity of background to examine the difference between Kv3.1b protein levels in SZ and control. Within these criteria for identifying a signal, the DLPFC (which has already been implicated in SZ with a decrease in PV) PC and OC were included (Figure 1 ).
Kv3.1b protein levels in the neocortex in SZ The expression level of Kv3.1b was contrasted, within those neocortical brain regions where the presence of Kv3.1b had been demonstrated, between well-matched SZ (N ¼ 12) and normal control (N ¼ 12) cases; post-mortem tissue quality characteristics were strong (Supplementary Table 1 ). In neocortical regions (DLPFC, PC and OC), there were no differences between these initial SZ and normal cases in Kv3.1b immunoreactivity ( (Figure 2a ). There were no significant correlations between Kv3.1b levels with age, RNA integrity numbers or post-mortem interval (all r between À 0.12 and 0.34, all P40.1), except between Kv3.1b protein levels in the OC and pH (r ¼ 0.57, P ¼ 0.007). Covarying for pH in the analysis of covariance did not alter the nonsignificance of group comparisons (F ¼ 0.6, d.f. ¼ 3,19, P ¼ 0.61). However, in this SZ Screening Cohort, a sample that included both on-and off-medication SZ cases (the few off-APD cases, to screen for potential APD effects), we noticed that the three SZ cases off-APD included showed low Kv3.1b levels; (Figure 2b ).
Kv3.1b mRNA levels in DLPFC in SZ Consistent with the reduction in neocortical Kv3.1b protein in drug-free SZ cases shown above, there was a decrease of Kv3.1b mRNA levels in the off-drug SZ cases in the SZ Off-APD Cohort (t ¼ 2.8, d.f. ¼ 1,14, P ¼ 0.01) (Figure 3b ), but not in the SZ Screening Cohort cases, in DLPFC (t ¼ 2.0, d.f. ¼ 1,22, P ¼ 0.84) (Figure 3a ).
Kv3.2 protein levels in the neocortex and subcortical regions in SZ Overall, no differences in the levels of Kv3.2 protein could be detected across the multiple Kv3.2-containing cerebral regions between SZ and normal tissue (Figure 4 and Supplementary   Figure 1) . In neocortical regions (DLPFC, OFC, ACC, PC and OC), there were no differences between the initial SZ and normal groups in Kv3.2 immunoreactivity (F ¼ 0.53, d.f. ¼ 4,88, P ¼ 0.7). There were significant correlations between Kv3.2 levels and age in the DLPFC (r ¼ 0.47, P ¼ 0.03) and OFC (r ¼ 0.5, P ¼ 0.02) and with pH in the ACC (r ¼ À 0.57, P ¼ 0.07). Including age and pH as covariates in the analysis of covariance did not alter the nonsignificance of group comparisons (F ¼ 0.15, d.f. ¼ 5,88, P ¼ 0.97). There were also no significant group differences in Kv3.2 levels in subcortical regions (F ¼ 1.29, d.f. ¼ 3,66, P ¼ 0.28). Again, in the SZ Off-APD Cohort, there were no differences within the SZ group in Kv3.2 levels in the (Figure 4b ).
Chronic antipsychotic drug effects on Kv3.1b proteins in rodent tissue Because levels of Kv3.1b subunit were reduced from normal in drug-free SZ tissue and were normal in APD-treated SZ cases, further demonstration of APD action on Kv3.1b subunit levels in mammalian brain tissue became important. Therefore, brain tissue from rodents treated chronically with APDs, which includes haloperidol (first-generation APD) or risperidone (second-generation APD), vs water was analyzed for Kv3 proteins. Chronic APD treatment in all rodents increased Kv3.1b in the No differences were seen in the screening cohort, but in the off-drug cohort Kv3.1b protein was significantly reduced in SZ tissue in the prefrontal cortex (P ¼ 0.03), parietal cortex (P ¼ 0.047) and showed a trend toward a reduction in occipital cortex (P ¼ 0.07) compared with control cases. The bottom picture shows representative blots of Kv3.1b and the internal control, b-actin for control and SZ, respectively. Open square represents SZ off-APD patients, and closed square represents SZ on-APD patients. *Po0.05; w Po0.08. APD, antipsychotic drug. 
DISCUSSION
There is not a full description of the distribution of Kv3.1b and Kv3.2 proteins in human brain (although the Allan Institute Brain Atlas contains human Kv3 microarray outcomes); therefore, these data defining regional Kv3.1b and Kv3.2 expression in humans are of consequence. The demonstration that Kv3.1b distribution is confined to the neocortex and is undetectable elsewhere, whereas Kv3.2 is abundant in human brain tissue and broadly represented, is likely to be consistent with their functions in mammalian brain. In addition, we report here that the levels of Kv3.1b protein are significantly reduced in SZ neocortex, but only in those SZ cases that are off medication, whereas the protein is normal in SZ on-APD cases. This supports the conclusion that low levels of Kv3.1b protein are a characteristic of SZ itself, whereas Kv3.1b levels in SZ are normal, only secondary to antipsychotic medication. Consistent with this finding, Kv3.1b levels are upregulated by chronic APD treatment in rat frontal cortex, confirming this as an action of APDs in mammalian PFC tissue. In addition, as low levels of Kv3.1b mRNA exist in off-APD but not in SZ on-APD in DLPFC, the mechanism of this APD effect appears to involve transcriptional regulation of the Kv3.1 gene. In contrast, it is important to note that Kv3.2 levels are not affected by APD treatment, providing a critical negative control to the Kv3.1b outcomes; no changes were found in Kv3.2 protein levels in SZ tissue in either SZ off-or SZ on-APD tissue. These analyses, showing a reduction of Kv3.1b protein in SZ tissue, can be parsimoniously interpreted to represent a reduction of Kv3.1b protein in the fast-spiking PV-containing GABA interneuron in SZ neocortex. While this outcome in SZ tissue is a reduction and not a full elimination, we can still expect aspects of the behavioral and electrophysiological alterations in the Kv3.1 KO mouse to map onto the phenotype of SZ. We know that the Kv3.1 knockout mouse shows increased locomotion and stereotypic behavior and sleep loss, 23 characteristics reminiscent of psychomotor excitement in SZ. However, it is the loss of the fast-spiking electrophysiological phenotype and the dysfunction in neuronal synchrony in the Kv3.1 KO animals that may be most pertinent to SZ. A reduction in the level of Kv3.1 protein in rodents is associated with a fundamental alteration in the firing pattern of the fast-spiking PV-containing GABA interneuron and a resultant alteration in the oscillatory synchrony function that these cells maintain in the brain. This detailed knowledge of the role of Kv3.1 in rodents 17, 19, 21 is the basis for the interpretation that in SZ, with low levels of Kv3.1 expression, the firing of the fast-spiking GABA interneuron is reduced and their role in supporting neuronal oscillatory function is likely compromised. That alterations in oscillatory activity in SZ have already been broadly demonstrated [5] [6] [7] [8] [9] [10] [11] [12] suggests that the finding of reduced Kv3.1b could be a critical and potentially explanatory feature of the gamma dys-synchrony phenotype in SZ. These data suggest that a fundamental reduction in Kv3.1 protein could alter the firing properties of the fast-spiking interneurons themselves. 17 A decrease in Kv3.1b channel subunits may be a critical dysfunctional element in DLPFC pathology in SZ, a defect that potentially drives the altered cerebral gamma oscillations in SZ.
Moreover, this alteration in K þ channel expression in the PV-containing GABA interneurons in SZ could potentially explain or be associated with other well-established molecular alterations in SZ brain, including the alterations in markers of GABA transmission in these cells. Altered expression of proteins related to GABAergic neurotransmission are present in SZ brain, a reduction that has been particularly well studied in the prefrontal cortex. 13 Studies from multiple laboratories show a reduction of glutamic acid decarboxylase 67 mRNA in SZ 14, 28, 29 and in PV-positive cells, [30] [31] [32] [33] a chemical marker for fast-spiking GABA neurons. In particular, glutamic acid decarboxylase 67 expression is decreased in PV-positive GABA-containing interneurons in SZ DLPFC. 30 These human data showing reduced GABA synthesis in PFC in SZ parallel findings in several animal models of SZ, including the prenatal methylazoxymethanol acetate-treated rat 34 and prenatal immune challenge using poly-IC, 35 as well as data from SZ risk gene mutant mice such as DISC1 (Disrupted-InSchizophrenia 1), 36, 37 where a decreased density in PV-positive interneurons is reported in the prefrontal cortex. Furthermore, a pharmacological model of SZ in animals using phencyclidinetreated rats shows reduced mRNA for PV and Kv3.1 in the prefrontal cortex. 38 Taken together with the evidence that the population of PV-expressing cells largely overlaps with the Kv3.1b-expressing cells in mouse neocortex, 39 these lines of evidence suggest that the decrease of Kv3.1b channel subunits could be associated with the decrease of PV in SZ and its animal models. On the other hand, these preclinical rodent models raise the possibility that expression of PV in interneurons is highly sensitive to various environmental and genetic risk factors for SZ. Considering that Kv3.1b, as a K þ channel, has a direct effect on the firing of the interneurons, the resulting decrease in Kv3.1b could be important in mediating alterations in brain function associated with psychiatric symptoms.
Although we had not predicted that antipsychotic treatment would increase Kv3.1b protein in the neocortex, the observations of this outcome in the data reported here is apparent from the human tissue studies and it is verified in our chronic APD-treated animal paradigm. The observation directly implicates the normalization of Kv3.1b protein levels as an aspect of the mechanism of action of antipsychotic drugs. Alterations in gamma synchrony and power have been described in SZ individuals who are treated with APDs; a direct effect of APD on gamma oscillations in untreated SZ has not yet been studied nor has the degree to which APDs fully normalize gamma band abnormalities been showed that there was a significant difference in Kv3.1b among three groups: haloperidol, risperidone and control groups (P ¼ 0.046). Post hoc t-tests showed a significant increase in Kv3.1b with haloperidol (P ¼ 0.004) and an increase, albeit not significant, with risperidone. There was no significant difference in the Kv3.1b protein increase between haloperidol and risperidone treatment. *Po0.005.
Kv3.1 potassium channel and schizophrenia M Yanagi et al determined. APDs, among their several actions, block D2 dopamine receptors, and have a robust therapeutic effect in psychosis, especially against psychomotor excitement. The mechanism through which APD action alters Kv3.1b protein in the neocortex is not known. The action could be a primary action of APDs at the K þ channel itself or an indirect action through dopamine receptor blockade elsewhere in the cortical-subcortical brain circuits.
Although the observations that associate neuronal dys-synchrony with symptom dimensions in SZ remain incompletely described and controversy exists, we speculate from the literature that impaired gamma power is associated largely with the psychosis phenotype in SZ. Some studies suggest that stimulusevoked gamma oscillations are decreased in SZ, especially across the frontal cortex, 4, 7, 40, 41 while Amann et al. 42 describe an increase in the levels of spontaneous gamma oscillations. These high levels of spontaneous gamma oscillations correlate with positive symptoms and could serve as markers of psychosis in SZ; 40 intense somatic hallucinations and reality distortions have been previously associated with high gamma oscillations. 43, 44 In support of the connection between high spontaneous gamma oscillations and psychosis in SZ are observations from N-methyl-D-aspartic acid (NMDA) antagonist-treated rodents. NMDA antagonists have a psychotomimetic effect in normal humans and increases positive symptoms in SZ. Moreover, NMDA antagonists increase spontaneous gamma oscillations in animals, 42, 45 whereas APD reduces these basal/spontaneous gamma oscillations. 42, 46 In addition, Kv3.1 KO mice show increased spontaneous gamma oscillations. 21 These multiple lines of evidence support the conjecture that decreased Kv3.1b protein is associated with the psychotic phenotype in SZ.
Previous genetic studies in SZ support the idea that impaired voltage-gated K þ channels could be involved in the illness. A brain-specific splicing variant of the KCNH2 gene encoding Kv11.1, another voltage-dependent K þ channel, has shown an association with SZ. 47 And, it has already been reported that antipsychotic drugs bind strongly to this channel and modulate the activity of the Kv11.1-containing neurons. 48 In addition, a large genomewide association study reported that the KCNC2 gene encoding Kv3.2 protein is associated with bipolar disorder, a condition closely related to SZ. 49 Given the fact that multiple K þ channels function together to modulate firing in a single neuron, it is possible that several different voltage-gated K þ channels are involved in the manifestations of SZ.
Overall, these data point to the existence of reductions in the Kv3.1b K þ channel subunit in SZ neocortex, but not the Kv3.2 protein, and to the involvement of this alteration in dys-inhibiting pyramidal cell firing in SZ neocortex and in modulating cortical firing to generate increases in gamma power, ultimately adversely affecting cognitive function in schizophrenia.
